Comparative efficacy and safety of picankibart versus guselkumab and tildrakizumab for moderate-to-severe plaque psoriasis: a systematic review and individual participant data-anchored population-adjusted network meta-analysis
AME Medical Journal · 2026-06 · 11 · 15-15
DOI: 10.21037/amj-2026-0041 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift AME Medical Journal, 2026-06. Verfasst von Mengxia Yan und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Yan, M., Chen, Y., Li, W., Bao, Y., Yao, K., & Wu, B. (2026). Comparative efficacy and safety of picankibart versus guselkumab and tildrakizumab for moderate-to-severe plaque psoriasis: a systematic review and individual participant data-anchored population-adjusted network meta-analysis. AME Medical Journal, 11, 15-15. https://doi.org/10.21037/amj-2026-0041
Vancouver
Yan M, Chen Y, Li W, Bao Y, Yao K, Wu B. Comparative efficacy and safety of picankibart versus guselkumab and tildrakizumab for moderate-to-severe plaque psoriasis: a systematic review and individual participant data-anchored population-adjusted network meta-analysis. AME Medical Journal. 2026;11:15-15. doi:10.21037/amj-2026-0041
BibTeX
@article{Yan2026,
author = {Yan, Mengxia and Chen, Ying and Li, Wen and Bao, Yun and Yao, Kaijie and Wu, Bin},
title = {Comparative efficacy and safety of picankibart versus guselkumab and tildrakizumab for moderate-to-severe plaque psoriasis: a systematic review and individual participant data-anchored population-adjusted network meta-analysis},
journal = {AME Medical Journal},
year = {2026},
volume = {11},
pages = {15--15},
doi = {10.21037/amj-2026-0041}
}
EUVIMED